Seeking Alpha

A few takeaways from Merck's (MRK +0.5%) presentation at Morgan Stanley's Healthcare Conference...

A few takeaways from Merck's (MRK +0.5%) presentation at Morgan Stanley's Healthcare Conference today: Seeing solid H1 sales growth in all major businesses; Anticipates US/EU filing for Odanacatib in H113, Tredaptive U.S. filing should come in H113 as well; Januvia showing solid sales growth, YTD June sales were $2.8B; Singulair's U.S. patent expired in August, the company has seen an 87% decline in prescriptions within just a few weeks. (Audio)
From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector